260 related articles for article (PubMed ID: 37424223)
21. Towards precision medicine in lymphoid malignancies.
Bühler MM; Martin-Subero JI; Pan-Hammarström Q; Campo E; Rosenquist R
J Intern Med; 2022 Aug; 292(2):221-242. PubMed ID: 34875132
[TBL] [Abstract][Full Text] [Related]
22. A multimodal genomics approach to diagnostic evaluation of pediatric hematologic malignancies.
Hiemenz MC; Oberley MJ; Doan A; Aye L; Ji J; Schmidt RJ; Biegel JA; Bhojwani D; Raca G
Cancer Genet; 2021 Jun; 254-255():25-33. PubMed ID: 33571894
[TBL] [Abstract][Full Text] [Related]
23. The characteristics and prognostic significance of the SET-CAN/NUP214 fusion gene in hematological malignancies: A systematic review.
Wang J; Zhan QR; Lu XX; Zhang LJ; Wang XX; Zhang HY
Medicine (Baltimore); 2022 Jul; 101(30):e29294. PubMed ID: 35905214
[TBL] [Abstract][Full Text] [Related]
24. FISH panels for hematologic malignancies.
Sreekantaiah C
Cytogenet Genome Res; 2007; 118(2-4):284-96. PubMed ID: 18000382
[TBL] [Abstract][Full Text] [Related]
25. [Introduction to the molecular diagnostic methods of oncohematology].
Király AP; Alpár D; Fésüs V; Marosvári D; Matolcsy A; Bödör C
Magy Onkol; 2016 Jun; 60(2):88-98. PubMed ID: 27275635
[TBL] [Abstract][Full Text] [Related]
26. [Necessity of Genetic Examination in Treatment for Hematological Malignancies].
Kiyoi H
Rinsho Byori; 2015 Mar; 63(3):369-76. PubMed ID: 26524860
[TBL] [Abstract][Full Text] [Related]
27. Individualizing treatment decisions for older adults with hematologic malignancies.
Klepin HD; Rizzieri D; Palumbo A; Magarotto V; Eichhorst B
Am Soc Clin Oncol Educ Book; 2013; ():208-19. PubMed ID: 23714504
[TBL] [Abstract][Full Text] [Related]
28. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.
Fukuhara S; Oshikawa-Kumade Y; Kogure Y; Shingaki S; Kariyazono H; Kikukawa Y; Koya J; Saito Y; Tabata M; Yoshifuji K; Mizuno K; Miyagi-Maeshima A; Matsushita H; Sugiyama M; Ogawa C; Inamoto Y; Fukuda T; Sugano M; Yamauchi N; Minami Y; Hirata M; Yoshida T; Kohno T; Kohsaka S; Mano H; Shiraishi Y; Ogawa S; Izutsu K; Kataoka K
Cancer Sci; 2022 Aug; 113(8):2763-2777. PubMed ID: 35579198
[TBL] [Abstract][Full Text] [Related]
29. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
30. Genomic technologies for detecting structural variations in hematologic malignancies.
Jang MA
Blood Res; 2024 Feb; 59(1):1. PubMed ID: 38485792
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization.
Döhner H; Stilgenbauer S; Fischer K; Schröder M; Bentz M; Lichter P
Stem Cells; 1995 Dec; 13 Suppl 3():76-82. PubMed ID: 8747992
[TBL] [Abstract][Full Text] [Related]
32. Precision Medicine in Therapy of Non-solid Cancer.
Schmidts I; Haferlach T; Hoermann G
Handb Exp Pharmacol; 2023; 280():35-64. PubMed ID: 35989345
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and classification of hematologic malignancies on the basis of genetics.
Taylor J; Xiao W; Abdel-Wahab O
Blood; 2017 Jul; 130(4):410-423. PubMed ID: 28600336
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA.
Coccaro N; Anelli L; Zagaria A; Tarantini F; Cumbo C; Tota G; Minervini CF; Minervini A; Conserva MR; Redavid I; Parciante E; Macchia MG; Specchia G; Musto P; Albano F
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296693
[TBL] [Abstract][Full Text] [Related]
35. [Advances in the target therapy of hematological malignancies].
Niu T; Liu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):642-6. PubMed ID: 25286692
[TBL] [Abstract][Full Text] [Related]
36. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
Tran TH; Hunger SP
Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
[TBL] [Abstract][Full Text] [Related]
37. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment.
Hemminki K; Hemminki J; Försti A; Sud A
Leukemia; 2023 Apr; 37(4):854-863. PubMed ID: 36828868
[TBL] [Abstract][Full Text] [Related]
38. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.
Sadeghi M; Khodakarami A; Ahmadi A; Fathi M; Gholizadeh Navashenaq J; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Movasaghpour Akbari AA; Jadidi-Niaragh F
Expert Opin Ther Targets; 2022 Dec; 26(12):1057-1071. PubMed ID: 36683579
[TBL] [Abstract][Full Text] [Related]
39. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
Vu M; Degeling K; Thompson ER; Blombery P; Westerman D; IJzerman MJ
Eur J Haematol; 2022 Jun; 108(6):469-485. PubMed ID: 35158410
[TBL] [Abstract][Full Text] [Related]
40. 11q23 abnormalities in adult Chinese patients with hematological malignancies.
Zhao X; Li S; Li N; Fan R; Lin G; Wang X
Med Oncol; 2014 Aug; 31(8):115. PubMed ID: 25008067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
